A new drug has shown major promise on its ability to suppress advanced lung cancer into a manageable chronic disease, ...

A vaccine against ALK-based resistance mutations induces immune responses against all of its targeted antigen in patients ...

This research, published in the Genes & Diseases journal by a team from Fujian Medical University and Sun Yat-Sen University, conducted a comprehensive bioinformatic and clinical analysis to examine ...

A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive ...

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for ...

Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer Clonal and subclonal mutations (variant allele frequency ≥5%) in ALK confer inferior prognosis for ...